BMJ 2001;323:1481-1484 ( 22-29 December )

...and thinking ahead

Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies

Maggie Somerset, lecturerMarjorie Weiss, lecturerTom Fahey, senior lecturer

Division of Primary Health Care, University of Bristol, Bristol BS6 6JL

Correspondence to: M Somerset m.somerset{at}bristol.ac.uk

Objectives: To examine the interaction between general practitioners and pharmaceutical company representatives.
Design: Qualitative study of 13 consecutive meetings between general practitioner and pharmaceutical representatives. A dramaturgical model was used to inform analysis of the transcribed verbal interactions.
Setting: Practice in south west England.
Participants: 13 pharmaceutical company representatives and one general practitioner.
Results: The encounters were acted out in six scenes. Scene 1 was initiated by the pharmaceutical representative, who acknowledged the relative status of the two players. Scene 2 provided the opportunity for the representative to check the general practitioner's knowledge about the product. Scene 3 was used to propose clinical and cost benefits associated with the product. During scene 4, the general practitioner took centre stage and challenged aspects of this information. Scene 5 involved a recovery strategy as the representative fought to regain equilibrium. In the final scene, the representative tried to ensure future contacts.
Conclusion: Encounters between general practitioners and pharmaceutical representatives follow a consistent format that is implicitly understood by each player. It is naive to suppose that pharmaceutical representatives are passive resources for drug information. General practitioners might benefit from someone who can provide unbiased information about prescribing in a manner that is supportive and sympathetic to the demands of practice.


What is already known on this topic
Pharmaceutical representatives influence physicians' prescribing in ways that are often unacknowledged by the physicians themselves

Meetings with pharmaceutical representatives are associated with increased prescribing costs and less rational prescribing

What this study adds
Meetings between pharmaceutical representatives and general practitioners follow a consistent format that is implicitly understood by each player

General practitioners may cooperate because representatives make them feel valued



© BMJ 2001

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Wick, C, Egger, M, Trelle, S, Juni, P, Fey, M. (2007). The characteristics of unsolicited clinical oncology literature provided by pharmaceutical industry. Ann Oncol 18: 1580-1582 [Full text]  
  • Chapman, S (2004). Advocacy for public health: a primer. J. Epidemiol. Community Health 58: 361-365 [Abstract] [Full text]  



Access jobs at BMJ Careers
Whats new online at Student 

BMJ